Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient

Current Infectious Disease Reports

Volumn 8, Issue 6, 2006, Pages 434-441

  Upton, Arlo ^a   Marr, Kieren A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABSIDIA; ACREMONIUM; ALLOGRAFT; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BLOOD CULTURE; CLINICAL TRIAL; CONFUSION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DEBRIDEMENT; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; FUNGUS IDENTIFICATION; FUSARIUM; GOLD STANDARD; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HALLUCINATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBARIC OXYGEN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LIVER DYSFUNCTION; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PAECILOMYCES; REVIEW; RHIZOPUS; RISK FACTOR; SCEDOSPORIUM APIOSPERMUM; SCOPULARIOPSIS BREVICAULIS; SYSTEMATIC REVIEW; T CELL DEPLETION; TRICHODERMA; VISUAL DISORDER; ZYGOMYCETES;

EID: 33750876577     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0017-5     Document Type: Review

References (51)

1. Slavin MA, Osborne B, Adams R, et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
2. Schell WA: New aspects of emerging fungal pathogens. A multifaceted challenge. Clin Lab Med 1995, 15:365-387.
3. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
4. Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
5. Nosari A, Oreste P, Cairoli R, et al.: Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001, 68:231-236.
6. Marr KA, Carter RA, Boeckh M, et al.: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
7. Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
8. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
9. Siwek GT, Pfaller MA, Polgreen PM, et al.: Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006, 55:209-212.
10. Wald A, Leisenring W, van Burik JA, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175:1459-1466.
11. Hachem RY, Kontoyiannis DP, Boktour MR, et al.: Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004, 101:1594-1600.
12. Lass-Florl C, Griff K, Mayr A, et al.: Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005, 131:201-207.
13. Perfect JR, Cox GM, Lee JY, et al.: The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33:1824-1833.
14. Pfaller MA, Messer SA, Hollis RJ, Jones RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032-1037.
15. Walsh TJ, Petraitis V, Petraitiene R, et al.: Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003, 188:305-319.
16. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001, 45:327-330.
17. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al.: Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004, 39:192-198.
18. Balajee SA, Gribskov JL, Hanley E, et al.: Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005, 4:625-632.
19. Balajee SA, Weaver M, Imhof A, et al.: Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004, 48:1197-1203.
20. Hong SB, Go SJ, Shin HD, et al.: Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia 2005, 97:1316-1329.
21. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
22. Upton A, Kirby KA, Boeckh M, et al.: Invasive aspergillosis following HSCT: Outcomes and prognostic factors associated with mortality [abstract 54]. Presented at the American Society for Blood and Marrow Transplantation meeting. Honolulu, HI; February 16-20, 2006.
23. Deresinski SC, Stevens DA: Caspofungin. Clin Infect Dis 2003, 36:1445-1457.
24. Munoz LS, Ruthazer R, Boucher H, et al.: Combination antifungals for primary treatment of invasive aspergillosis (IA): do they work? Paper presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19,2005.
25. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
26. MacCallum DM, Whyte JA, Odds FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005, 49:3697-3701.
27. Perea S, Gonzalez G, Fothergill AW, et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039-3041.
28. Girmenia C, Pagano L, Corvatta L, et al.: The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol 2000, 111:272-276.
29. Nucci M, Anaissie EJ, Queiroz-Telles F, et al.: Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
30. Nucci M, Mart KA, Queiroz-Telles F, et al.: Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
31. Boutati EI, Anaissie EJ: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
32. Nucci M, Anaissie E: Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002, 35:909-920.
33. Johnson EM, Szekely A, Warnock DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998, 42:741-745.
34. Cudillo L, Girmenia C, Santilli S, et al.: Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005, 40:1212-1213.
35. Raad II, Hachem RY, Herbrecht R, et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
36. Richter S, Cormican MG, Pfaller MA, et al.: Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. J Clin Microbiol 1999, 37:1154-1160.
37. Chan-Tack KM, Thio CL, Miller NS, et al.: Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol 1999, 37:57-60.
38. Pfaller MA, Diekema DJ: Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419-4431.
39. Steinbach WJ, Schell WA, Miller JL, et al.: Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. J Infect 2004, 48:112-116.
40. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
41. Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
42. Maertens J, Demuynck H, Verbeken EK, et al.: Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999, 24:307-312.
43. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al.: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
44. Vigouroux S, Morin O, Moreau P, et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35-37.
45. Bialek R, Konrad F, Kern J, et al.: PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005, 58:1180-1184.
46. Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
47. John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515-517.
48. Revankar SG, Patterson JE, Sutton DA, et al.: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002, 34:467-476.
49. Husain S, Munoz P, Forrest G, et al.: Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005, 40:89-99.
50. Whyte M, Irving H, O'Regan P, et al.: Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005, 24:375-377.
51. Howden BP, Slavin MA, Schwarer AP, Mijch AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003, 22:111-113.